Prevention of De Novo Hepatitis B in Recipients of Core Antibody-Positive Livers With Lamivudine and Other Nucleos(t)ides

Abstract

LAM monoprophylaxis was effective in preventing de novo HBV in the vast majority of recipients over long-term follow-up. Adefovir had a higher rate of de novo infections numerically, whereas tenofovir and entecavir had no cases and may be more effective, but this was limited by a small sample size.